STOCK TITAN

[8-K] Dyadic International, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Dyadic International, Inc. (Nasdaq: DYAI) received a Nasdaq Listing Qualifications notice on 17-Jul-2025 after its common stock failed to meet the $1.00 minimum bid price for the past 30 consecutive business days, violating Rule 5550(a)(2).

The notice does not immediately affect DYAI’s listing. The company has 180 calendar days—until 13-Jan-2026—to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive trading days. If the requirement is unmet, Dyadic may qualify for a second 180-day grace period, provided it satisfies all initial listing standards other than bid price and formally notifies Nasdaq of its remediation plan. Failure to cure could result in delisting, with the option to appeal.

Management “intends to actively monitor” share price and explore alternatives to resolve the deficiency. The filing also reminds investors that the company remains out of compliance with the $35 million Market Value of Listed Securities rule (Rule 5550(b)(2)); that separate deficiency must be remedied by 20-Dec-2025. Either unresolved deficiency can independently trigger delisting.

Dyadic International, Inc. (Nasdaq: DYAI) ha ricevuto un avviso di qualificazione per la quotazione Nasdaq il 17-lug-2025 dopo che il prezzo delle sue azioni ordinarie è sceso sotto il minimo di $1,00 per azione per 30 giorni lavorativi consecutivi, violando la Regola 5550(a)(2).

L'avviso non incide immediatamente sulla quotazione di DYAI. La società ha 180 giorni di calendario—fino al 13-gen-2026—per tornare in conformità raggiungendo un prezzo di chiusura di almeno $1,00 per 10 giorni di negoziazione consecutivi. Se il requisito non viene soddisfatto, Dyadic può ottenere un secondo periodo di grazia di 180 giorni, a condizione che rispetti tutti gli standard iniziali di quotazione eccetto il prezzo e notifichi formalmente a Nasdaq il piano di risanamento. Il mancato adeguamento potrebbe portare alla cancellazione dalla quotazione, con possibilità di appello.

La direzione “intende monitorare attivamente” il prezzo delle azioni ed esplorare alternative per risolvere la carenza. Il comunicato ricorda inoltre agli investitori che la società è ancora non conforme alla regola sul Valore di Mercato dei Titoli Quotati di $35 milioni (Regola 5550(b)(2)); questa seconda non conformità deve essere risolta entro il 20-dic-2025. Ognuna delle due carenze non risolte può indipendentemente causare la cancellazione dalla quotazione.

Dyadic International, Inc. (Nasdaq: DYAI) recibió un aviso de calificación para la cotización en Nasdaq el 17-jul-2025 tras no cumplir con el precio mínimo de oferta de $1.00 durante los últimos 30 días hábiles consecutivos, violando la Regla 5550(a)(2).

El aviso no afecta inmediatamente la cotización de DYAI. La compañía tiene 180 días calendario—hasta el 13-ene-2026—para recuperar el cumplimiento logrando un precio de cierre de al menos $1.00 durante 10 días de negociación consecutivos. Si no se cumple el requisito, Dyadic puede calificar para un segundo período de gracia de 180 días, siempre que cumpla con todos los estándares iniciales de cotización excepto el precio y notifique formalmente a Nasdaq su plan de remediación. La falta de corrección podría resultar en la exclusión de la cotización, con opción a apelación.

La dirección “planea monitorear activamente” el precio de las acciones y explorar alternativas para resolver la deficiencia. El aviso también recuerda a los inversores que la compañía sigue fuera de cumplimiento con la regla del Valor de Mercado de Valores Cotizados de $35 millones (Regla 5550(b)(2)); esta deficiencia separada debe remediarse antes del 20-dic-2025. Cualquiera de las deficiencias no resueltas puede causar la exclusión de forma independiente.

Dyadic International, Inc. (Nasdaq: DYAI)2025년 7월 17일, 지난 30거래일 연속으로 $1.00 최저 입찰가를 충족하지 못해 규칙 5550(a)(2)를 위반하여 나스닥 상장 자격 통지를 받았습니다.

이 통지는 DYAI의 상장에 즉시 영향을 미치지 않습니다. 회사는 2026년 1월 13일까지 180일 동안 10거래일 연속으로 최소 $1.00의 종가를 달성하여 규정을 준수해야 합니다. 요건을 충족하지 못할 경우, Dyadic은 입찰가를 제외한 초기 상장 기준을 모두 충족하고 나스닥에 개선 계획을 공식 통지하면 두 번째 180일 유예 기간을 받을 수 있습니다. 개선 실패 시 상장 폐지될 수 있으며, 이의 신청이 가능합니다.

경영진은 주가를 “적극적으로 모니터링”하고 문제 해결을 위한 대안을 모색할 계획입니다. 또한 회사가 $3,500만 상장 증권 시가총액 규정 (규칙 5550(b)(2))을 여전히 준수하지 못하고 있음을 투자자에게 상기시키며, 이 별도의 문제는 2025년 12월 20일까지 해결해야 합니다. 두 가지 미해결 문제 중 어느 하나라도 독립적으로 상장 폐지를 초래할 수 있습니다.

Dyadic International, Inc. (Nasdaq : DYAI) a reçu un avis de qualification de cotation Nasdaq le 17 juillet 2025 après que le cours de son action ordinaire n’ait pas respecté le prix d’offre minimum de 1,00 $ pendant 30 jours ouvrables consécutifs, violant la règle 5550(a)(2).

L’avis n’affecte pas immédiatement la cotation de DYAI. La société dispose de 180 jours calendaires—jusqu’au 13 janvier 2026—pour se conformer en atteignant un cours de clôture d’au moins 1,00 $ pendant 10 jours de bourse consécutifs. Si cette exigence n’est pas remplie, Dyadic peut bénéficier d’une seconde période de grâce de 180 jours, à condition de satisfaire à toutes les normes initiales de cotation sauf le prix d’offre et de notifier formellement Nasdaq de son plan de redressement. Le défaut de correction pourrait entraîner une radiation, avec possibilité d’appel.

La direction « a l’intention de surveiller activement » le cours de l’action et d’explorer des alternatives pour résoudre cette insuffisance. Le dépôt rappelle également aux investisseurs que la société reste non conforme à la règle sur la valeur de marché des titres cotés de 35 millions de dollars (règle 5550(b)(2)) ; cette autre insuffisance doit être corrigée avant le 20 décembre 2025. Chacune des insuffisances non résolues peut entraîner indépendamment une radiation.

Dyadic International, Inc. (Nasdaq: DYAI) erhielt am 17. Juli 2025 eine Nasdaq-Listing-Qualifikationsmitteilung, nachdem der Kurs der Stammaktie in den letzten 30 aufeinanderfolgenden Handelstagen unter dem Mindestgebotspreis von 1,00 $ lag und somit gegen Regel 5550(a)(2) verstoßen wurde.

Die Mitteilung hat keinen unmittelbaren Einfluss auf die Notierung von DYAI. Das Unternehmen hat 180 Kalendertage – bis zum 13. Januar 2026, um die Anforderungen wieder zu erfüllen, indem es an 10 aufeinanderfolgenden Handelstagen einen Schlusskurs von mindestens 1,00 $ erreicht. Wird die Anforderung nicht erfüllt, kann Dyadic eine zweite 180-tägige Nachfrist erhalten, sofern alle anderen Anfangsnotierungsstandards außer dem Gebotspreis eingehalten werden und Nasdaq formell über den Sanierungsplan informiert wird. Ein Versäumnis kann zur Delistung führen, mit der Möglichkeit zur Berufung.

Das Management „beabsichtigt, den Aktienkurs aktiv zu überwachen“ und alternative Lösungen zur Behebung des Mangels zu prüfen. Die Mitteilung erinnert Investoren zudem daran, dass das Unternehmen weiterhin nicht den Anforderungen an den Marktwert der gelisteten Wertpapiere von 35 Millionen $ (Regel 5550(b)(2)) entspricht; dieser separate Mangel muss bis zum 20. Dezember 2025 behoben werden. Jede der beiden nicht behobenen Mängel kann unabhängig eine Delistung auslösen.

Positive
  • 180-day grace period gives Dyadic time to regain compliance before any listing penalty.
Negative
  • Bid-price deficiency adds to existing MVLS shortfall, heightening delisting probability.
  • Company provided no concrete corrective actions, leaving uncertainty around compliance strategy.

Insights

TL;DR: Dual Nasdaq deficiencies increase delisting risk; timeline gives Dyadic limited room to act.

The bid-price notice compounds Dyadic’s existing MVLS shortfall and signals heightened listing risk. Although the 180-day window is standard, the coinciding Dec-2025 MVLS deadline leaves only a narrow margin for simultaneous remediation. The share price’s sub-$1 level also restricts capital-raising flexibility, potentially tightening liquidity. Investors should watch for reverse-split proposals, strategic updates, or partnerships aimed at both value creation and price support. Until tangible corrective steps emerge, the filing skews negative for valuation and liquidity perceptions.

TL;DR: Governance procedures intact, but cumulative compliance gaps pose credibility risk.

The company followed disclosure rules promptly, which is positive from a governance standpoint. However, serial rule violations undermine board credibility and could affect institutional investor confidence. The filing outlines potential appeals, yet success rates are modest unless operational metrics improve. Management’s plan to “evaluate available options” lacks specificity, suggesting no ready remedy. Governance best practices would call for transparent action plans—including possible reverse split thresholds, cost controls or asset monetisation—well before the grace periods expire.

Dyadic International, Inc. (Nasdaq: DYAI) ha ricevuto un avviso di qualificazione per la quotazione Nasdaq il 17-lug-2025 dopo che il prezzo delle sue azioni ordinarie è sceso sotto il minimo di $1,00 per azione per 30 giorni lavorativi consecutivi, violando la Regola 5550(a)(2).

L'avviso non incide immediatamente sulla quotazione di DYAI. La società ha 180 giorni di calendario—fino al 13-gen-2026—per tornare in conformità raggiungendo un prezzo di chiusura di almeno $1,00 per 10 giorni di negoziazione consecutivi. Se il requisito non viene soddisfatto, Dyadic può ottenere un secondo periodo di grazia di 180 giorni, a condizione che rispetti tutti gli standard iniziali di quotazione eccetto il prezzo e notifichi formalmente a Nasdaq il piano di risanamento. Il mancato adeguamento potrebbe portare alla cancellazione dalla quotazione, con possibilità di appello.

La direzione “intende monitorare attivamente” il prezzo delle azioni ed esplorare alternative per risolvere la carenza. Il comunicato ricorda inoltre agli investitori che la società è ancora non conforme alla regola sul Valore di Mercato dei Titoli Quotati di $35 milioni (Regola 5550(b)(2)); questa seconda non conformità deve essere risolta entro il 20-dic-2025. Ognuna delle due carenze non risolte può indipendentemente causare la cancellazione dalla quotazione.

Dyadic International, Inc. (Nasdaq: DYAI) recibió un aviso de calificación para la cotización en Nasdaq el 17-jul-2025 tras no cumplir con el precio mínimo de oferta de $1.00 durante los últimos 30 días hábiles consecutivos, violando la Regla 5550(a)(2).

El aviso no afecta inmediatamente la cotización de DYAI. La compañía tiene 180 días calendario—hasta el 13-ene-2026—para recuperar el cumplimiento logrando un precio de cierre de al menos $1.00 durante 10 días de negociación consecutivos. Si no se cumple el requisito, Dyadic puede calificar para un segundo período de gracia de 180 días, siempre que cumpla con todos los estándares iniciales de cotización excepto el precio y notifique formalmente a Nasdaq su plan de remediación. La falta de corrección podría resultar en la exclusión de la cotización, con opción a apelación.

La dirección “planea monitorear activamente” el precio de las acciones y explorar alternativas para resolver la deficiencia. El aviso también recuerda a los inversores que la compañía sigue fuera de cumplimiento con la regla del Valor de Mercado de Valores Cotizados de $35 millones (Regla 5550(b)(2)); esta deficiencia separada debe remediarse antes del 20-dic-2025. Cualquiera de las deficiencias no resueltas puede causar la exclusión de forma independiente.

Dyadic International, Inc. (Nasdaq: DYAI)2025년 7월 17일, 지난 30거래일 연속으로 $1.00 최저 입찰가를 충족하지 못해 규칙 5550(a)(2)를 위반하여 나스닥 상장 자격 통지를 받았습니다.

이 통지는 DYAI의 상장에 즉시 영향을 미치지 않습니다. 회사는 2026년 1월 13일까지 180일 동안 10거래일 연속으로 최소 $1.00의 종가를 달성하여 규정을 준수해야 합니다. 요건을 충족하지 못할 경우, Dyadic은 입찰가를 제외한 초기 상장 기준을 모두 충족하고 나스닥에 개선 계획을 공식 통지하면 두 번째 180일 유예 기간을 받을 수 있습니다. 개선 실패 시 상장 폐지될 수 있으며, 이의 신청이 가능합니다.

경영진은 주가를 “적극적으로 모니터링”하고 문제 해결을 위한 대안을 모색할 계획입니다. 또한 회사가 $3,500만 상장 증권 시가총액 규정 (규칙 5550(b)(2))을 여전히 준수하지 못하고 있음을 투자자에게 상기시키며, 이 별도의 문제는 2025년 12월 20일까지 해결해야 합니다. 두 가지 미해결 문제 중 어느 하나라도 독립적으로 상장 폐지를 초래할 수 있습니다.

Dyadic International, Inc. (Nasdaq : DYAI) a reçu un avis de qualification de cotation Nasdaq le 17 juillet 2025 après que le cours de son action ordinaire n’ait pas respecté le prix d’offre minimum de 1,00 $ pendant 30 jours ouvrables consécutifs, violant la règle 5550(a)(2).

L’avis n’affecte pas immédiatement la cotation de DYAI. La société dispose de 180 jours calendaires—jusqu’au 13 janvier 2026—pour se conformer en atteignant un cours de clôture d’au moins 1,00 $ pendant 10 jours de bourse consécutifs. Si cette exigence n’est pas remplie, Dyadic peut bénéficier d’une seconde période de grâce de 180 jours, à condition de satisfaire à toutes les normes initiales de cotation sauf le prix d’offre et de notifier formellement Nasdaq de son plan de redressement. Le défaut de correction pourrait entraîner une radiation, avec possibilité d’appel.

La direction « a l’intention de surveiller activement » le cours de l’action et d’explorer des alternatives pour résoudre cette insuffisance. Le dépôt rappelle également aux investisseurs que la société reste non conforme à la règle sur la valeur de marché des titres cotés de 35 millions de dollars (règle 5550(b)(2)) ; cette autre insuffisance doit être corrigée avant le 20 décembre 2025. Chacune des insuffisances non résolues peut entraîner indépendamment une radiation.

Dyadic International, Inc. (Nasdaq: DYAI) erhielt am 17. Juli 2025 eine Nasdaq-Listing-Qualifikationsmitteilung, nachdem der Kurs der Stammaktie in den letzten 30 aufeinanderfolgenden Handelstagen unter dem Mindestgebotspreis von 1,00 $ lag und somit gegen Regel 5550(a)(2) verstoßen wurde.

Die Mitteilung hat keinen unmittelbaren Einfluss auf die Notierung von DYAI. Das Unternehmen hat 180 Kalendertage – bis zum 13. Januar 2026, um die Anforderungen wieder zu erfüllen, indem es an 10 aufeinanderfolgenden Handelstagen einen Schlusskurs von mindestens 1,00 $ erreicht. Wird die Anforderung nicht erfüllt, kann Dyadic eine zweite 180-tägige Nachfrist erhalten, sofern alle anderen Anfangsnotierungsstandards außer dem Gebotspreis eingehalten werden und Nasdaq formell über den Sanierungsplan informiert wird. Ein Versäumnis kann zur Delistung führen, mit der Möglichkeit zur Berufung.

Das Management „beabsichtigt, den Aktienkurs aktiv zu überwachen“ und alternative Lösungen zur Behebung des Mangels zu prüfen. Die Mitteilung erinnert Investoren zudem daran, dass das Unternehmen weiterhin nicht den Anforderungen an den Marktwert der gelisteten Wertpapiere von 35 Millionen $ (Regel 5550(b)(2)) entspricht; dieser separate Mangel muss bis zum 20. Dezember 2025 behoben werden. Jede der beiden nicht behobenen Mängel kann unabhängig eine Delistung auslösen.

false 0001213809 0001213809 2025-07-17 2025-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): July 17, 2025

 

 

 

 

Dyadic International, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-32513   45-0486747

(State or other jurisdiction

of incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

 

1044 North U.S. Highway One, Suite 201

Jupiter, FL 33477

(Address of principal executive offices and zip code)

 

(561) 743-8333

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   DYAI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

(a)

 

On July 17, 2025, Dyadic International, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Nasdaq Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days the Company’s securities have not maintained the minimum bid price of at least $1 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until January 13, 2026 (the “Compliance Date”), to regain compliance with the minimum bid price requirement by having the Company’s bid price close at $1 per share or more for a minimum of 10 consecutive business days before the Compliance Date (subject to the Staff’s discretion to extend this period under Nasdaq Listing Rule 5810(c)(3)(H)). If the Company does not regain compliance by the Compliance Date, the Company may be eligible for an additional 180-day period to regain compliance, provided that on the Compliance Date the Company meets the applicable market value of publicly held shares requirement for continued listing and all other applicable standards for initial listing on the Nasdaq Capital Market (except the bid price requirement) based on the Company’s most recent public filings and market information and notifies Nasdaq of its intent to cure this deficiency. However, if it appears to the Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible for the second compliance period, and the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that the Company’s common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful.

 

The Company intends to actively monitor the bid price of its common stock between now and the Compliance Date and, as appropriate, plans to evaluate available options to resolve the deficiency and regain compliance with the minimum bid price requirement.

 

As previously disclosed, the Company also remains out of compliance with the minimum Market Value of Listed Securities (“MVLS”) of $35 million required by the continued listing requirements of Nasdaq Listing Rule 5550(b)(2), and has until December 20, 2025 to regain compliance with such requirement. The bid price deficiency discussed in the Notice is a separate and unrelated deficiency, and either deficiency, if not cured by the applicable deadline, could be a basis for the delisting of the Company’s common stock.

 

Safe Harbor Regarding Forward-Looking Statements

 

This current report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, including those regarding the Company’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, including its plan to regain compliance with Nasdaq Listing Rule 5550(a)(2). Forward-looking statements involve many risks, uncertainties or other factors beyond the Company’s control. These factors include, but are not limited to, the following: (i) the Company’s history of net losses; (ii) the Company’s ability to maintain compliance with other Nasdaq continued listing standards and rules, including the minimum MVLS rule; (iii) the Company’s capital needs; and (iv) other factors impacting the Company’s business, results of operations and stock price, including market and regulatory acceptance of the Company’s microbial protein production platforms and other technologies, failure to commercialize the Company’s microbial protein production platforms or the Company’s other technologies, competition, including from alternative technologies, the results of nonclinical studies and clinical trials, changes in global economic and financial conditions, the Company’s reliance on information technology, the Company’s dependence on third parties, government regulations and environmental, social and governance issues, and intellectual property risks. For a more complete description of the risks that could cause the Company’s actual results to differ from the Company’s current expectations, please see the section entitled “Risk Factors” in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”), as such factors may be updated from time to time in the Company’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. All forward-looking statements speak only as of the date made, and except as required by applicable law, the Company assumes no obligation to publicly update any such forward-looking statements for any reason after the date of this Current Report on Form 8-K to conform these statements to actual results or to changes in the Company’s expectations.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 23, 2025

 

  Dyadic International, Inc.
     
  By: /s/ Ping Rawson
  Name:

Ping Rawson

  Title:

Chief Financial Officer

 

 

FAQ

Why did Dyadic International (DYAI) receive a Nasdaq deficiency notice?

Because DYAI’s stock traded below $1.00 for 30 consecutive business days, breaching Listing Rule 5550(a)(2).

What is Dyadic’s deadline to regain the $1 bid price compliance?

The company has until 13-Jan-2026 to achieve a $1.00 bid for at least 10 straight trading days.

Does the notice immediately delist Dyadic’s shares?

No. The notice has no immediate effect; trading continues on Nasdaq Capital Market during the grace period.

What happens if Dyadic fails to meet the bid price requirement by the deadline?

Nasdaq may grant an additional 180-day extension or issue a delisting notice, which Dyadic could appeal.

What other Nasdaq rule is Dyadic currently violating?

DYAI is also non-compliant with the $35 million Market Value of Listed Securities requirement, with a cure deadline of 20-Dec-2025.

What steps does Dyadic plan to take to regain compliance?

Management stated it will monitor share price and evaluate options; specific measures were not detailed in the filing.
Dyadic Intl Inc Del

NASDAQ:DYAI

DYAI Rankings

DYAI Latest News

DYAI Latest SEC Filings

DYAI Stock Data

29.49M
20.97M
30.15%
17.3%
0.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
JUPITER